Leucocyte depletion of perioperative blood transfusion does not affect long-term survival and recurrence in patients with gastrointestinal cancer

被引:33
作者
Lange, M. M. [1 ]
van Hilten, J. A. [3 ]
van de Watering, L. M. G. [3 ]
Bijnen, B. A. [4 ]
Roumen, R. M. H. [5 ]
Putter, H. [2 ]
Brand, A. [3 ]
van de Velde, C. J. H. [1 ]
机构
[1] Leiden Univ, Dept Surg, Med Ctr, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Dept Med Stat & Bioinformat, Med Ctr, NL-2300 RC Leiden, Netherlands
[3] Leiden Univ, Dept Immunohaematol & Blood Transfus, Med Ctr & Sanquin Blood Supply, NL-2300 RC Leiden, Netherlands
[4] Med Ctr Alkmaar, Dept Surg, Alkmaar, Netherlands
[5] Maxima Med Ctr, Dept Surg, Veldhoven, Netherlands
关键词
RANDOMIZED CONTROLLED-TRIAL; COLORECTAL-CANCER; SURGERY; IMMUNOMODULATION; COMPLICATIONS; COMPONENTS; PROGNOSIS; CELLS;
D O I
10.1002/bjs.6636
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Perioperative red blood cell (RBC) transfusion may be associated with a poor prognosis in cancer surgery. Allogeneic leucocytes are assumed to play a causal role. This study evaluated the long-term effect of transfusion with leucocyte-depleted (LD) blood in patients with gastrointestinal cancer. Methods: The Transfusion Associated Complications = Transfusion Induced Complications? (TACTIC) study is a multicentre randomized controlled trial evaluating the short-term benefits of LD versus non-LD RBC transfusions. The present study evaluated 5-year survival and cancer recurrence among 512 patients with gastrointestinal cancer included in the TACTIC study. Results: Some 89.2 per cent of patients had a primary tumour and 79.7 per cent underwent surgery with curative intent; 243 patients received perioperative RBC transfusion (median 3 units). The 5-year overall survival rate of patients with any type of gastrointestinal cancer was 50.8 per cent in the LD group and 45.8 per cent in the non-LD group (P = 0.191). Corresponding 5-year disease-free survival rates were 60.0 and 56.6 per cent (P = 0.482), and recurrence rates 32.9 and 34.3 per cent (P = 0.864). Conclusion: Leucocyte depletion is not associated with better long-term survival and lower recurrence rates in patients with gastrointestinal cancer.
引用
收藏
页码:734 / 740
页数:7
相关论文
共 20 条
[1]   BLOOD-TRANSFUSION AND PROGNOSIS IN DUKES B AND C COLORECTAL-CANCER [J].
BENTZEN, SM ;
BALSLEV, I ;
PEDERSEN, M ;
TEGLBJAERG, PS ;
HANBERGSORENSEN, F ;
BONE, J ;
JACOBSEN, NO ;
SELL, A ;
OVERGAARD, J ;
BERTELSEN, K ;
HAGE, E ;
FENGER, C ;
KRONBORG, O ;
HANSEN, L ;
HOSTRUP, H ;
NORGAARDPEDERSEN, B .
EUROPEAN JOURNAL OF CANCER, 1990, 26 (04) :457-463
[2]  
BLUMBERG N, 1994, ARCH PATHOL LAB MED, V118, P371
[3]   EXPERIMENTAL ANIMAL-MODEL OF REFRACTORINESS TO DONOR PLATELETS - THE EFFECT OF PLASMA REMOVAL AND THE EXTENT OF WHITE CELL-REDUCTION ON ALLOGENEIC ALLOIMMUNIZATION [J].
BORDIN, JO ;
BARDOSSY, L ;
BLAJCHMAN, MA .
TRANSFUSION, 1993, 33 (10) :798-801
[4]   RELATIONSHIP BETWEEN BLOOD-TRANSFUSION AND TUMOR BEHAVIOR [J].
FRANCIS, DMA .
BRITISH JOURNAL OF SURGERY, 1991, 78 (12) :1420-1428
[5]  
GANTT CL, 1981, LANCET, V2, P363
[6]   In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules: do they play a role in autologous blood transfusion? [J].
Ghio, M ;
Contini, P ;
Mazzei, C ;
Merlo, A ;
Filaci, G ;
Setti, M ;
Indiveri, F ;
Puppo, F .
TRANSFUSION, 2001, 41 (08) :988-996
[7]   RANDOMIZED CONTROLLED TRIAL COMPARING TRANSFUSION OF LEUKOCYTE-DEPLETED OR BUFFY-COAT-DEPLETED BLOOD IN SURGERY FOR COLORECTAL-CANCER [J].
HOUBIERS, JGA ;
BRAND, A ;
VANDEWATERING, LMG ;
HERMANS, J ;
VERWEY, PJM ;
BIJNEN, AB ;
PAHLPLATZ, P ;
SCHATTENKERK, ME ;
WOBBES, T ;
DEVRIES, JE ;
KLEMENTSCHITSCH, P ;
VANDEMAAS, AHM ;
VANDEVELDE, CJH .
LANCET, 1994, 344 (8922) :573-578
[8]   Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery [J].
Jensen, LS ;
KissmeyerNielsen, P ;
Wolff, B ;
Qvist, N .
LANCET, 1996, 348 (9031) :841-845
[9]   Are allogeneic blood transfusions acceptable in elective surgery in colorectal carcinoma? Pro [J].
Marquet, RL ;
Busch, ORC ;
Jeekel, J .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (03) :352-353
[10]   THE USE OF LEUKOCYTE-REDUCED BLOOD COMPONENTS [J].
MILLER, JP ;
MINTZ, PD .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1995, 9 (01) :69-90